If the drug Mannitol is not given to the kidney donor during the removal of the kidney, does it adversely affect short term function of the kidney in the patient receiving the kidney?
Phase 3
Completed
- Conditions
- Health Condition 1: null- Renal transplant recipients.
- Registration Number
- CTRI/2015/11/006371
- Lead Sponsor
- Institutional Research Board
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
All adults undergoing renal transplantation at CMC Vellore will be included after informed consent.
Exclusion Criteria
Age >70 years, recipient BMI >30 kg/m2, multiple renal arteries in donor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum creatineTimepoint: Day 7 post renal transplant.
- Secondary Outcome Measures
Name Time Method Histopathological evidence of acute tubular necrosis.Timepoint: 1. After the completion of vascular anastomosis in renal transplant. <br/ ><br>2. In case biopsy is performed as a result of suspected rejection in the first week after transplant.;Need for dialysisTimepoint: First week post transplant.;Serum creatinineTimepoint: Day 30 post transplant.;Serum cystatinTimepoint: Pre-op, day 1 and day 3 post transplant.;Urine NGAL (Neutrophil Gelatinase-Associated Lipocalin).Timepoint: 18 hrs post transplant.